Today: 17 July 2026
Browse Category

Stock Market 10 February 2026

CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL announced Tuesday that Chief Executive Paul McKenzie is stepping down, with Gordon Naylor stepping in as interim CEO and managing director beginning Feb. 11. McKenzie, who came aboard as chief operating officer in 2019, moved up to the CEO post in March 2023. During his tenure, CSL rolled out new treatments, including Hemgenix, its gene therapy for haemophilia B. Naylor, previously finance chief and head of the Seqirus vaccines division, took a board seat in December.
Go toTop